Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025–2027
The results underscore the growing financial impact of orphan drugs on Italy's healthcare budget. This analysis offers a quantitative projection of the resources required to ensure continued access to innovative therapies for RDs.
Authors
- Marzia Bonfanti
- F Luccini
- M Guardigni
- Claudio Jommi (ORCID: https://orcid.org/0000-0002-2862-2990)
- Rossella Bitonti (ORCID: https://orcid.org/0000-0002-2639-1113)
- Chiara Lucchetti
- Andrea Aiello
- Pier Luigi Canonico
- Andrea Marcellusi
- Daniela Cazzato
- Giulio Guarnotta
Institutions
- University of Rome Tor Vergata (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- University of Milan (IT)
- Paladin Pharma (Italy) (IT)
Publication Details
- Journal
- Health Economics Review
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1186/s13561-025-00699-4
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00